Masif pulmoner emboli hastalarında trombolitik ajan olarak kullanılan alteplaz ve reteplazın klinik etkinliğinin retrospektif değerlendirilmesi

Abstract

Amaç: Masif pulmoner emboli hastalarında alteplaz ve reteplazın klinik etkinliğinin karşılaştırılması. Gereç ve Yöntemler: 2010-2016 yılları arasında masif pulmoner emboli nedeniyle trombolitik tedavi olarak alteplaz ya da reteplaz verilen tüm hastalar çalışmaya alındı. Demografik veriler, bazal, 2., 4., 6., 12., ve 24. saatteki hemodinamik parametreler, erken ve geç mortalite ile kanama komplikasyonları karşılaştırıldı. Bulgular: Yaş ortalaması 64.2±13.6 yıl olan toplam 75 hasta, (32 alteplaz, 43 reteplaz ) çalışmaya alındı. Her iki grupta da hemodinamik parametrelerde anlamlı düzelme saptandı. Sistolik kan basıncında bazal değerlere göre 6. ve 12. saatlerdeki artış alteplaz grubunda reteplaz grubundan anlamlı olarak daha yüksek bulundu. Mortalite ve majör kanama her iki grupta da benzer bulundu. Minör kanama ise alteplaz grubunda reteplaz grubuna göre anlamlı olarak daha yüksek saptandı, sırasıyla %28,1 vs %2,3. Sonuç: Masif pulmoner emboli hastalarında trombolitik tedavide reteplaz, alteplaz kadar etkin ve güvenli görünmektedir.

Keywords

• Alteplaz
• doku plazminojen aktivatörü
• pulmoner emboli
• reteplaz trombolizis

Retrospective evaluation of two different thrombolytic agents in the treatment of patients with massive pulmonary embolism: Alteplase vs reteplase

Abstract

Aim: To compare clinical effectiveness of reteplase and alteplase in patients with massive pulmonary embolism. Material and Methods: Between 2010 and 2016 all patients treated with one of the thrombolytic agents, alteplase or reteplase, for massive pulmonary embolism were eligible for the study. We compared demographic data, hemodynamic parameters at baseline and at 2th, 4th, 6th, 12th, 24th hours after thrombolysis, the early and 1 year mortality rates and bleeding complications between two groups. Results: Seventy five patients (32 alteplase and 43 reteplase) were included study. Mean age was 64.2±13.6 years. Compared to the baseline values, hemodynamic parameters improved significantly at 2th, 4th, 6th, 12th and 24th hours after thrombolysis in both groups. In alteplase group, systolic blood pressure between baseline and at 6th and 12th hours altered significantly when compared with reteplase group. No significant difference was found in mortality rates and major bleeding events between groups. Minor bleeding events were higher in alteplase group than reteplase group, 28.1% vs 2.3%, respectively and the difference was significant. Conclusion: Reteplase seems as safe and effective as alteplase in the thrombolytic treatment of patients with massive pulmonary embolism.

Keywords

• Alteplase
• pulmonary embolism
• reteplase
• tissue plasminogen activator
• thrombolysis

References

1. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing JH, Harjola VP, et al, ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC) Eur Heart J. 2020;41(4):543-603. https://doi.org/10.1093/eurheartj/ehz405
2. Wendelboe AM, Raskob GE. Global Burden of Thrombosis: Epidemiologic Aspects. Circ Res. 2016;118(9):1340-1347. https://doi.org/10.1161/CIRCRESAHA.115.306841
3. Limbrey R, Howard L. Developments in the management and treatment of pulmonary embolism. Eur Respir Rev. 2015;24(137):484-497. https://doi.org/10.1183/16000617.00006614
4. Almoosa K. Is thrombolytic therapy effective for pulmonary embolism? Am Fam Physician. 2002;65(6):1097-1103.
5. Bĕlohlávek J, Dytrych V, Linhart A. Pulmonary embolism, part II: management. Exp Clin Cardiol. 2013;18(2):139-147.
6. Lankeit, M, Jiménez D, Kostrubiec M, Dellas C, Hasenfuss G, Pruszczyk P, Konstantinides S. Predictive value of the high-sensitivity troponin T assay and the simplified Pulmonary Embolism Severity Index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study. Circulation. 2011;124(24):2716-2724. https://doi.org/10.1161/CIRCULATIONAHA.111.051177
7. Riera-Mestre A, Becattini C, Giustozzi M, Agnelli G. Thrombolysis in hemodynamically stable patients with acute pulmonary embolism: a meta-analysis. Thromb Res. 2014;134(6):1265-1271. https://doi.org/10.1016/j.thromres.2014.10.004
8. Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation. 2011;123(16):1788-1830. https://doi.org/10.1161/CIR.0b013e318214914f

9. Logan JK, Pantle H, Huiras P, Bessman E, Bright L. Evidence-based diagnosis and thrombolytic treatment of cardiac arrest or periarrest due to suspected pulmonary embolism. Am J Emerg Med. 2014;32(7):789-796. https://doi.org/10.1016/j.ajem.2014.04.032
10. Gao GY, Yang P, Liu M, Ding M, Liu GH, Tong YL, et al. Thrombolysis for acute intermediate-risk pulmonary embolism: a meta-analysis. Thromb Res. 2015;136(5):932-937. https://doi.org/10.1016/j.thromres.2015.09.012
11. Jiménez D, Aujesky D, Moores L, Gómez V, Lobo J. L, Uresandi F, et al, RIETE investigators. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med. 2010;170(15):1383-1389. https://doi.org/10.1001/archinternmed.2010.199
12. Otero R, Trujillo-Santos J, Cayuela A, Rodríguez C, Barron M, Martin JJ, et al. Registro Informatizado de la Enfermedad Tromboembólica (RIETE) Investigators. Haemodynamically unstable pulmonary embolism in the RIETE Registry: systolic blood pressure or shock index? Eur Respir J. 2007;30(6):1111-1116. https://doi.org/10.1183/09031936.00071007
13. Capstick T, Henry MT. Efficacy of thrombolytic agents in the treatment of pulmonary embolism. Eur Respir J. 2005;26(5):864-874. https://doi.org/10.1183/09031936.05.00002505
14. Simpson D, Siddiqui MAA, Scott LJ, Hilleman DE. Reteplase: a review of its use in the management of thrombotic occlusive disorders. Am J Cardiovasc Drugs. 2006;6(4):265-285. https://doi.org/10.2165/00129784-200606040-00007
15. Dasbiswas A, Hiremath J, Trailokya A. Overview of reteplase, A novel thrombolytic agent in Indian context. Cardiol Pharmacol. 2015;4:136-142.
16. Harter K, Levine M, Henderson SO. Anticoagulation drug therapy: a review. West J Emerg Med. 2015;16(1):11-17. https://doi.org/10.5811/westjem.2014.12.22933
17. Hasdai D, Holmes Jr DR, Topol EJ, Berger PB, Criger DA, Hochman JS, et al. Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. Eur Heart J. 1999;20(2):128-135. https://doi.org/10.1053/euhj.1999.1282
18. Martin U, Kaufmann B, Neugebauer G. Current clinical use of reteplase for thrombolysis: a pharmacokinetic-pharmacodynamic perspective. Clin Pharmacokinet. 1999;36(4):265-276.
19. Nordt TK, Bode C. Thrombolysis: newer thrombolytic agents and their role in clinical medicine. Heart. 2003;89(11):1358-1362. https://doi.org/10.1136/heart.89.11.1358
20. Tebbe U, Graf A, Kamke W, Zahn R, Forycki F, Kratzsch G, et al. Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism. Am Heart J. 1999;138(1):39-44. https://doi.org/10.1016/s0002-8703(99)70243-7
21. Liu Z, Wang J. Thrombolytic application of reteplase and the change of pulmonary arterial pressure in pulmonary embolism. Heart. 2011;97(Suppl 3):A188-A189.
22. Kuisma M, Silfvast T, Voipio V, Malmström R. Prehospital thrombolytic treatment of massive pulmonary embolism with reteplase during cardiopulmonary resuscitation. Resuscitation. 1998;38(1):47-50. https://doi.org/10.1016/s0300-9572(98)00066-5
23. Sharif-Kashani B, Kiani A, Bakhshayesh-Karam M, Sheybani-Afshar F, Behzadnia N, Naghash-Zadeh F. Hemodynamic and symptomatic improvement after delayed thrombolysis with Reteplase in a patient with massive bilateral pulmonary emboli. Blood Coagul Fibrinolysis. 2015;26(1):88-90. https://doi.org/10.1097/MBC.0000000000000087
24. Zuo Z, Yue J, Dong BR, Wu T, Liu GJ, Hao Q. Thrombolytic therapy for pulmonary embolism. Cochrane Database Syst Rev. 2021;4(4):CD004437. https://doi.org/10.1002/14651858.CD004437.pub6
25. Xu Q, Huang K, Zhai Z, Yang Y, Wang J, Wang C. Initial thrombolysis treatment compared with anticoagulation for acute intermediate-risk pulmonary embolism: a meta-analysis. J Thorac Dis. 2015;7(5):810-821. https://doi.org/10.3978/j.issn.2072-1439.2015.04.51
26. İpek G, Karataş MB, Onuk T, Güngör B, Yüzbaş B, Keskin M, et al. Effectiveness and safety of thrombolytic therapy in elderly patients with pulmonary embolism. J Thromb Thrombolysis. 2015;40(4):424-429. https://doi.org/10.1007/s11239-015-1214-6
27. Chalikias GK, Tziakas DN, Stakos DA, Konstantinides SV. Management of acute pulmonary embolism: a contemporary, risk-tailored approach. Hellenic J Cardiol. 2010;51(5):437-450.
28. Sharifi M, Vajo Z, Freeman W, Bay C, Sharifi M, Schwartz F. Transforming and simplifying the treatment of pulmonary embolism:“safe dose” thrombolysis plus new oral anticoagulants. Lung. 2015;193:369-374. https://doi.org/10.1007/s00408-015-9702-1
29. Marti C, John G, Konstantinides S, Combescure C, Sanchez O, Lankeit M, et al. Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. Eur Heart J. 2015;36(10):605-614. https://doi.org/10.1093/eurheartj/ehu218.
30. Grunwald MR, Hofmann LV. Comparison of urokinase, alteplase, and reteplase for catheter-directed thrombolysis of deep venous thrombosis. J Vasc Interv Radiol. 2004;15(4):347-352. https://doi.org/10.1097/01.rvi.0000121407.46920.15
31. Daley MJ, Murthy MS, Peterson EJ. Bleeding risk with systemic thrombolytic therapy for pulmonary embolism: scope of the problem. Ther Adv Drug Saf. 2015;6(2):57-66. https://doi.org/10.1177/2042098615572333